| n | 108 | 356 | 718 |
| Male sex, n (%) | 56 (51) | 180 (51) | 357 (50) |
| Age, mean (SD) | 72 (10) | 71 (10) | 70 (10) |
| | | |
| Prevalence (per 1000 patients) | 1.2 | 1.4 | 2.4 |
| | | |
| Stage at presentation, n (%) | | | |
| 1 | 20 (19) | 45 (13) | 100 (14) |
| 2 | 6 (6) | 34 (10) | 55 (8) |
| 3 | 33 (31) | 98 (28) | 214 (30) |
| 4 | 49 (45) | 179 (50) | 349 (49) |
| | | |
| Performance status, n (%) | | | |
| 0 | 18 (17) | 45 (13) | 68 (10) |
| 1 | 44 (41) | 119 (33) | 216 (30) |
| 2 | 20 (19) | 106 (30) | 207 (29) |
| 3 | 12 (11) | 48 (14) | 125 (17) |
| 4 | 5 (5) | 10 (3) | 33 (5) |
| Not recorded | 9 (8) | 28 (8) | 69 (10) |
| | | |
| Tissue diagnosis attempted, n (%) | 92 (85) | 298 (84) | 597 (83) |
| | | |
| Treatment, n (%) | | | |
| Best supportive care | 27 (25) | 95 (27) | 242 (34) |
| Palliative XRT | 31 (29) | 87 (24) | 164 (23) |
| Chemotherapy | 21 (19) | 103 (29) | 183 (26) |
| Surgery/radical radiotherapy | 29 (27) | 71 (20) | 129 (18) |
| | | | |
| Median survival, median days (95%CI) | 210 (124–296) | 173 (142–204) | 155 (130–180) |